Vestibular schwannomas, also called acoustic neuromas, affect roughly one in every 100,000 people each year. Although benign and often slow-growing, these tumors sit in the cerebellopontine angle, a cramped compartment at the base of the brain where the auditory and vestibular nerves exit the brainstem. As they enlarge, they can press against these nerves and surrounding structures, producing progressive hearing loss on one side, tinnitus, imbalance, and in larger cases facial weakness or life-threatening brainstem compression. Management options span a spectrum: watchful waiting with serial magnetic resonance imaging, stereotactic radiosurgery using precisely focused radiation beams, or microsurgical resection through one of several skull-base approaches. Each strategy carries distinct risks and benefits, and the choice depends on tumor size, hearing status, patient age, and patient preference. Over the past half-century, management trends in the United States have shifted markedly, with observation and radiosurgery claiming growing shares of newly diagnosed patients while open surgery has become more selective.

Clinicians have accumulated a substantial body of evidence on how these treatments affect hearing, facial nerve function, vertigo, and overall quality of life. Longitudinal studies and large cross-sectional surveys have compared disease-specific quality of life across microsurgery, radiosurgery, and observation, generally finding that patient-reported outcomes converge over time and that factors such as vertigo, anxiety, and hearing status often matter more to patients than the treatment modality itself. What has been far less studied is the economic experience of the patient behind the MRI scans and audiograms. Earlier investigations into the socioeconomic impact of acoustic neuroma surgery, some dating back to the late 1990s, documented that a meaningful fraction of patients reduced their working hours or left the workforce, and European registry data have shown that vertigo in particular predicts future work disability. Meanwhile, a parallel literature on cost-effectiveness has compared the health-system costs of surgery, radiosurgery, and surveillance, including lifetime cost modeling and analyses of screening MRI protocols for asymmetric hearing loss.

What those cost analyses capture is the perspective of insurers and health systems: procedure fees, imaging expenses, hospital stays, and follow-up care. They do not capture what economists and oncologists have come to call financial toxicity, the cumulative personal financial strain experienced by patients and families, including out-of-pocket costs, lost wages, debt, and the psychological distress that accompanies them. In cancers such as breast, prostate, thyroid, and head and neck malignancy, financial toxicity has emerged as a clinically relevant patient-reported outcome, associated in some studies with worse quality of life and even with treatment nonadherence. Validated instruments now exist to measure it, most prominently the Comprehensive Score for financial Toxicity, an eleven-item questionnaire whose acronym COST reflects its purpose, and the Financial Distress Questionnaire, which grades distress from none to severe. The Ohio State team recognized that no study had systematically applied these tools to vestibular schwannoma patients, whose benign diagnosis and varied management pathways might produce a very different financial profile from malignant cancer.

To fill that gap, the researchers designed a cross-sectional survey and distributed it through the Acoustic Neuroma Association, a national patient support organization whose membership provided access to individuals across the spectrum of treatment experiences. The questionnaire asked respondents about their personal finances and employment before and after tumor management, with particular emphasis on financial toxicity as measured by the COST instrument and the Financial Distress Questionnaire. By the time the study closed, 41 respondents had fully completed the survey. The demographic profile skewed older and female: 24 participants, or 59 percent, were older than fifty at the time of their intervention, and 33 participants, or 80 percent, were women. Treatment distribution reflected contemporary practice patterns, with 29 respondents, 71 percent, reporting microsurgical resection of their tumor, 9 respondents, 22 percent, reporting radiation therapy, and 3 respondents, 7 percent, describing a combination of both modalities.

The employment findings were striking even if the financial scores were not. After initiation of management, 11 respondents, or 27 percent, experienced a change in employment altogether, while 17 respondents, or 41 percent, reported a change in their duties at work, a category that encompassed reduced hours, diminished activity, or new unemployment. In other words, more than four in ten patients felt the tumor or its treatment reshape their working lives in some tangible way. This aligns with older socioeconomic studies and with more recent European data showing that vestibular schwannoma and its management can affect employment status, work capacity, and productivity, with predictors including age, gender, tumor size, and persistent symptoms such as dizziness. Yet when the researchers quantified the subjective financial burden using validated scales, the picture softened considerably.

On the COST questionnaire, which scores financial toxicity on a scale where lower numbers indicate greater distress, the median score among respondents was 32, with an interquartile range of 15 to 39. On the Financial Distress Questionnaire, only 4 respondents, or 10 percent, were classified as having moderate financial toxicity, and just 2 respondents, or 5 percent, reported severe financial toxicity. Taken together, the results suggest that although employment disruption is common after vestibular schwannoma management, the ultimate financial toxicity of these changes appears limited, with few patients experiencing substantial personal financial hardship. The authors caution, however, that the survey design cannot disentangle whether this relative resilience reflects the benign nature of the disease, the demographics of the respondent pool, the structure of insurance coverage in the United States, or the support resources available through patient advocacy networks.

The study carries important caveats that the researchers themselves emphasize. A sample of 41 self-selected respondents recruited through a patient support organization is small and unlikely to be representative of the broader vestibular schwannoma population, which includes many patients under observation who may never join advocacy groups. Cross-sectional surveys also capture a snapshot rather than a trajectory, so they cannot track how financial toxicity evolves from diagnosis through treatment and recovery, nor can they establish causal links between a specific treatment modality and later financial outcomes. The collected data are not publicly available, though the authors note they may be shared upon request pending appropriate institutional approval and a data use agreement. The study was conducted without internal or external funding, was deemed exempt by The Ohio State University institutional review board, and all participants provided electronic consent before taking part.

Even with those limitations, the research opens a conversation that neuro-oncology has largely avoided. As treatment decisions for vestibular schwannoma increasingly become shared decisions between patients and multidisciplinary teams, information about the likely personal economic consequences of surgery, radiosurgery, or observation could prove as valuable to patients as hearing preservation rates or facial nerve outcomes. The authors call for prospective studies with larger and more diverse cohorts to better identify the risk factors that predispose individual patients to personal financial difficulty, whether those risks involve younger age at diagnosis, pre-treatment employment in physically demanding work, vertigo that persists after treatment, or gaps in insurance coverage. For now, the message for patients facing a vestibular schwannoma diagnosis is cautiously reassuring: the tumor may change how you work, but for most people in this survey, it did not devastate the household balance sheet. Bridging the gap between employment disruption and financial resilience, and understanding who falls through it, is the task the researchers say must come next.

Subject of Research: The personal financial impact and financial toxicity of vestibular schwannoma management in surveyed patients

Article Title: Assessing the personal financial impact of vestibular schwannoma management

Article References: Macielak, R. J., Liu, W., Andresen, N. S., Ren, Y., Dodson, E. E., Prevedello, D. M., Adunka, O. F., Wu, K. C., & Schoo, D. P. (2026). Assessing the personal financial impact of vestibular schwannoma management. Journal of Neuro-Oncology, 179(2), Article 76. https://doi.org/10.1007/s11060-026-05797-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05797-9

Keywords: vestibular schwannoma, acoustic neuroma, financial toxicity, microsurgery, radiosurgery, employment, COST questionnaire, Financial Distress Questionnaire, quality of life, patient survey, neuro-oncology, outcomes research